blepharospasm
Conditions
Interventions
None listed
Sponsors
Miyata Eye Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with primary and drug induced blepharospasm The control group is consist of patients without blepharospasm and receiving none of treatment Best corrected visual acuity of each eyes is 1.0 and more
Exclusion criteria
Exclusion criteria: 1) Symptomatic eyelid spasm Patients with a history of Parkinson's disease, progressive supranuclear palsy, etc. 2) History of botulinum toxin treatment within 6 months prior to survey. 3) Patients with systemic neuromuscular junction disorders. Myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, etc. 4) Patients with cerebrovascular disease with paralysis 5) Patients with facial nerve palsy 6) Patients with glaucoma or ocular hypertension under treatment 7) Patients with active uveitis 8) Patients with corneal and conjunctival diseases, excluding dry eyes 9) Patients with macular diseases (e.g. age-related macular degeneration, epiretinal membrane, etc.) 10) Patients with retinal diseases (e.g., retinal vascular disorder, retinitis pigmentosa, myopic changes, etc.) 11)Patients with intense myopia greater than -6D 12) Other patients who are deemed inappropriate by the physician, such as those with systemic or ophthalmic diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| functional visual acuity | — |
Secondary
| Measure | Time frame |
|---|---|
| visual acuity, subjective manifest refraction, intraocular pressure, assessment of corneal epithelial fluorescein staining (NEI score), tear film break up time (BUT), dry eye questionnaire-5 (DEQ-5), blepharospasm disability index (BSDI), Jancovic rating scale (JRS) | — |
Countries
Japan
Contacts
Public ContactToshihiro Sakisaka
Miyata Eye Hospital Medical Office
Outcome results
None listed